Evidence map›Paper›PMID 36497082›Full record

ReviewCells2022

The Role of Bone Morphogenetic Protein Receptor Type 2 (

Anichavezhi Devendran, Sumanta Kar, Rasheed Bailey, Maria Giovanna Trivieri

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Use of iPSC-Derived Smooth Muscle Cells to Model Physiology and Pathology.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Anichavezhi DevendranCardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-2483-7660
Sumanta KarCardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Rasheed BaileyCardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Maria Giovanna TrivieriCardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-6601-3267
Icahn School of Medicine at Mount Sinai · US

Funding

MSHS Translational Science HubKL2TR001435 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MOSKOWITZ, ALAN J · 2015 to 2019
$3.8M
NCATS NIH HHS KL2 TR001435
6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary vascular resistance (PVR), causing right ventricular hypertrophy and ultimately death from right heart failure. Heterozygous mutations in the bone morphogenetic protein receptor type 2 (

Indexed as

Hypertension, PulmonaryInduced Pluripotent Stem CellsPulmonary Arterial HypertensionAnimalsBone Morphogenetic Protein Receptors, Type IIHumansPulmonary ArterySignal TransductionBMPR2 protein, humanBone Morphogenetic Protein Receptors, Type IIbone morphogenetic protein receptor type 2disease modelinginduced pluripotent stem cellpulmonary arterial endothelial cellspulmonary arterial hypertensionpulmonary arterial smooth muscle cellspulmonary vascular resistancevascular remodeling

Identifiers

PMID36497082
PMCPMC9741276
OpenAlexW4310990391

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.